Part D beneficiaries may pay more for some generics, biosimilars than brand name drugs

16 July 2019 - Medicare Part D enrolees may actually pay more for some generic drugs than they would for their ...

Read more →

Majority of patients not asked for consent before being switched to a biosimilar, survey finds

17 July 2019 - The preliminary survey results showed that 52% of patients received a letter from hospital about switching to ...

Read more →

Biosimilars continue to exhibit market failure

11 July 2019 - From their inception, biosimilars in the U.S. have faced headwinds.  ...

Read more →

Pfizer receives U.S. FDA approval for its first biosimilar, Zirabev (bevacizumab-bvzr)

28 June 2019 - Pfizer today announced the U.S. FDA has approved Zirabev (bevacizumab-bvzr), a biosimilar to Avastin (bevacizumab), for the ...

Read more →

Forcing patients to switch to biosimilars puts them in uncharted waters

23 June 2019 - On May 27, the B.C. government announced a policy that will forcibly switch thousands of patients, ...

Read more →

How big pharma suppresses ‘biosimilars’

23 June 2019 - Deals with insurers and pharmacy benefit managers at patient and taxpayer expense. ...

Read more →

European Medicines Agency accepted first "China-Developed" biosimilar - Henlius HLX02 marketing authorisation application for review

21 June 2019 - First China-developed trastuzumab biosimilar accepted for MAA review by the EMA. ...

Read more →

Combatting misinformation on biosimilars and preparing the market for them can save the U.S. billions

19 June 2019 - As politicians and policymakers debate effective ways to rein in rising health care costs, biosimilars represent ...

Read more →

Advisory Council supports biosimilars in call for universal public drug coverage in Canada

17 June 2019 - A Canadian advisory council is recommending the use of biosimilars in a final report that lays ...

Read more →

Ensuring innovation and competition for biologics leads to more timely products for patients

13 June 2019 - Today, the FDA approved the agency’s 20th biosimilar product, Kanjinti (trastuzumab-anns), for the treatment of patients with ...

Read more →

Amgen wins FDA approval for Kanjinti injection for treatment of breast cancer, gastro-esophageal junction adenocarcinoma

13 June 2019 - U.S. FDA says Kanjinti (trastuzumab-anns) is biosimilar to Herceptin (trastuzumab). ...

Read more →

Realigning incentives to optimise generic and biosimilar prescribing

13 June 2019 - Drug prices and their impact on total US health care expenditures are again front of mind ...

Read more →

Should the FDA disclose new filings for drugs, biologics and biosimilars?

11 June 2019 - In 2010, the FDA issued draft recommendations on increasing the transparency of the FDA’s processes and ...

Read more →

Systematic literature review calls economic impact of switching to biosimilars "uncertain"

10 June 2019 - Biosimilar drugs are intended by their developers to provide a cost-saving alternative to brand-name biologics, and ...

Read more →

Biosimilar proposal for Medicare will depend on the details

11 June 2019 - Last month, the Biosimilars Forum released a proposal that it said could save the United States ...

Read more →